Claims
- 1. A purified polypeptide comprising a unique amino acid region of SEQ. ID. NO. 1, SEQ. ID. NO. 2, or SEQ. ID. NO. 3 that is at least 9 contiguous amino acids in length, wherein said unique region is not present in SEQ. ID. NO. 7.
- 2. The polypeptide of claim 1, wherein said unique region comprises an amino acid sequence selected from the group consisting of:
- 3. The polypeptide of claim 1, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2, and SEQ. ID. NO. 3.
- 4. The polypeptide of claim 3, wherein said polypeptide consists of an amino acid sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2, and SEQ. ID. NO. 3.
- 5. The polypeptide of claim 1, wherein said polypeptide consists of an amino acid sequence having a sequence identity of at least 70% with SEQ. ID. NO. 1.
- 6. A purified nucleic acid comprising a nucleotide sequence encoding for the polypeptide of claim 1.
- 7. A purified nucleic acid comprising a nucleotide sequence encoding for the polypeptide of claim 5.
- 8. A purified nucleic acid comprising a unique nucleotide sequence region of SEQ. ID. NO. 4, SEQ. ID. NO. 5, SEQ. ID. NO. 6 or the complement thereof, that is at least 18 contiguous nucleotides in length, wherein said unique region is not present in SEQ. ID. NO. 8 or the complement thereof.
- 9. The purified nucleic acid of claim 8, wherein said unique region comprises a sequence selected from the group consisting of:
- 10. The purified nucleic acid of claim 8, wherein said nucleic acid comprises a sequence selected from the group consisting of the nucleotide sequence of SEQ. ID. NO. 4, SEQ. ID. NO. 5 and SEQ. ID. NO. 6.
- 11. The purified nucleic acid of claim 10, wherein said nucleic acid consists of a sequence selected from the group consisting of the nucleotide sequence of SEQ. ID. NO. 4, SEQ. ID. NO. 5 and SEQ. ID. NO. 6.
- 12. An expression vector comprising a recombinant nucleotide sequence encoding for a unique amino acid region of SEQ. ID. NO. 1, SEQ. ID. NO. 2, or SEQ. ID. NO. 3 that is at least 9 contiguous amino acids in length, wherein said unique region is not present in SEQ. ID. NO. 7.
- 13. The expression vector of claim 12, wherein said recombinant nucleotide sequence encodes for a polypeptide comprising a sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2 and SEQ. ID. NO. 3.
- 14. A recombinant cell comprising the expression vector of claim 12, wherein said recombinant nucleotide sequence is functionally coupled to a promoter recognized by said cell.
- 15. A recombinant cell comprising the expression vector of claim 13, wherein said recombinant nucleotide sequence is functionally coupled to a promoter recognized by said cell.
- 16. A recombinant cell made by a process comprising the step of introducing into said cell the expression vector of claim 12, wherein said recombinant nucleotide sequence is functionally coupled to a promoter recognized by said cell.
- 17. A purified antibody preparation comprising an antibody that binds a polypeptide selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2 and SEQ. ID. NO. 3.
- 18. The antibody of claim 17, wherein said polypeptide consists of the amino acid sequence of SEQ. ID. NO. 19 (LGKRITMRKTRCQQLAKLAEQ HRQR).
- 19. A method of preparing a GABA-gated chloride polypeptide comprising the step of incubating a cell comprising a recombinant nucleotide sequence encoding for a unique amino acid region of SEQ. ID. NO. 1, SEQ. ID. NO. 2, or SEQ. ID. NO. 3 that is at least 9 contiguous amino acids in length, wherein said unique region is not present in SEQ. ID. NO. 7, under conditions wherein said polypeptide is expressed.
- 20. A method for assaying the binding of a compound to a D. variabilis GABA-gated chloride channel comprising the steps of:
a) expressing from a recombinant nucleic acid a polypeptide comprising a unique amino acid region of SEQ. ID. NO. 1, SEQ. ID. NO. 2, or SEQ. ID. NO. 3 that is at least 9 contiguous amino acids in length, wherein said unique region is not present in SEQ. ID. NO. 7; b) providing to said polypeptide a test preparation comprising one or more test compounds; and c) measuring the ability of said test preparation to bind to said polypeptide.
- 21. The method of claim 20, wherein said polypeptide consists of 9 contiguous amino acids up to the full-length sequence provided in SEQ. ID. NOs. 1, 2, or 3.
- 22. The method of claim 21, wherein said steps (b) and (c) are performed in vitro.
- 23. The method of claim 21, wherein said steps (a), (b) and (c) are performed using a whole cell.
- 24. The method of claim 21, wherein said polypeptide is expressed from an expression vector.
- 25. The method of claim 24, wherein said polypeptide consists of a sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2 and SEQ. ID. NO. 3.
- 26. A method of measuring GABA-gated chloride channel activity comprising the steps of:
a) contacting a recombinant cell with a compound, wherein said recombinant cell comprises a recombinant nucleotide sequence expressing a functional GABA-gated chloride channel that comprises a unique amino acid region of SEQ. ID. NO. 1, SEQ. ID. NO. 2, or SEQ. ID. NO. 3 that is at least 9 contiguous amino acids in length, provided that said unique region is not present in SEQ. ID. NO. 7; and b) measuring GABA-gated chloride channel activity.
- 27. The method of claim 26, wherein said functional GABA-gated chloride channel comprises an amino sequence having a sequence identity of at least 70% with SEQ. ID. NO. 1.
- 28. The method of claim 26, wherein said functional GABA-gated chloride channel comprises a sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2 and SEQ. ID. NO. 3.
- 29. The method of claim 26, wherein said functional GABA-gated chloride channel consists of a sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2 and SEQ. ID. NO. 3.
- 30. A method of decreasing or preventing a tick infestation comprising the steps of:
a) identifying a compound that modulates a D. variabilis GABA-gated chloride channel activity; and b) using said compound to decrease or prevent a tick infestation.
- 31. The method of claim 30, wherein said step (a) is performed by (i) contacting a recombinant cell with said compound, wherein said recombinant cell comprises a recombinant nucleotide sequence expressing a functional GABA-gated chloride channel that comprises a unique amino acid region of SEQ. ID. NO. 1, SEQ. ID. NO. 2, or SEQ. ID. NO. 3 that is at least 9 contiguous amino acids in length, provided that said unique region is not present in SEQ. ID. NO. 7 and (ii) measuring GABA-gated chloride channel activity.
- 32. The method of claim 31, wherein said functional GABA-gated chloride channel comprises a sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2, and SEQ. ID. NO. 3.
- 33. The method of claim 32, wherein said functional GABA-gated chloride channel consists of a sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2, and SEQ. ID. NO. 3.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority to provisional application U.S. Serial No. 60/193,791, filed Mar. 31, 2000, hereby incorporated by reference herein.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US01/09955 |
3/28/2001 |
WO |
|